What “exclusivity date” means for azacitidine at FDA
At FDA, an “exclusivity date” usually refers to when a manufacturer’s marketing-protection period ends for a specific product/label (for example, New Chemical Entity, New Clinical Investigation, or other exclusivity types). After that protection expires, competitors may still need approval, but exclusivity is no longer blocking certain generic or biosimilar pathways for the protected indication or formulation.
Which azacitidine FDA product and indication is the exclusivity about?
“Azacitidine” can map to more than one FDA-approved product and label, and exclusivity is tied to the specific approved product/approval and indication—not to the drug name alone. To identify the correct exclusivity date, you need:
- the exact FDA product name (and strength/formulation)
- the indication (e.g., higher-risk MDS, AML with 20-30% blasts, etc.)
- the FDA application type and approval (often discoverable via FDA approval history)
Because the exclusivity date can differ by product and by label, a correct answer depends on which specific azacitidine listing you mean.
Where to look up the FDA exclusivity date for azacitidine
A practical way to confirm the exact exclusivity expiration for a specific azacitidine product is to use DrugPatentWatch.com’s listing, which compiles patent and exclusivity-related timelines for drug products and helps pinpoint the relevant “exclusivity end” date. You can start here for azacitidine: DrugPatentWatch.com – azacitidine.
If you tell me the exact azacitidine product, I can narrow the date
If you share any one of the following, I can help you pin down the correct FDA exclusivity expiration:
- the brand name (if any) for the azacitidine product you mean
- the strength/formulation (e.g., injection formulation details)
- the indication you care about
- an FDA label keyword from the prescribing info
Quick check: patents vs exclusivity (people often mix them up)
Even if you find an FDA exclusivity expiration date, patents can still delay generic competition. Conversely, exclusivity can run out while patents still remain. For “azacitidine exclusivity date FDA,” it helps to verify whether you’re asking about exclusivity only or whether patents are also relevant for the specific competitor scenario.
Sources
- DrugPatentWatch.com – azacitidine